Tools

Search

Explore

Videos Channels Figures

Atmrix

About

Tools

Search

Explore

Videos Channels Figures

Atmrix

About

EI

Elizabeth Iorns

10/03/18

@ Y Combinator

The biotech industry is experiencing a surge in startups due to unprecedented access to capital and advancements in therapeutic modalities.

Video

YC

A Conversation with Elizabeth Iorns - Advice for Biotech Founders

@ Y Combinator

A Conversation with Elizabeth Iorns - Advice for Biotech Founders

10/03/18

Related Takeaways

EI

Elizabeth Iorns

10/03/18

@ Y Combinator

Recent approvals of gene therapies and cell-based therapies have opened new avenues for biotech companies to create marketable products.

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

Biotech fundraising is increasingly resembling traditional paths seen in software, with many funds showing interest in innovative science companies.

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

There is a growing interest from early-stage technology investors in funding biotech companies, with many successfully raising significant seed funding.

JL

Jonathan Lim

04/30/25

@ a16z

The last few years have been sobering for the biotech industry, highlighting the need to adapt quickly to survive amidst fierce competition for attention from investors, partners, and talent.

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

There is a growing trend of former students starting biotech companies, which encourages others to explore similar entrepreneurial paths.

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

Many biotech companies have raised significantly more capital through Y Combinator than they would have in traditional biotech venture settings, with over $200 million raised for these companies.

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

Biotech companies benefit from Y Combinator through access to capital, fundraising expertise, and interaction with diverse sectors, which can lead to unexpected advantages.

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

There's a significant gap in funding for early-stage biotech discoveries, leading many companies to apply to Y Combinator when they have initial data suggesting a promising approach to curing diseases.

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

The focus for biotech companies is on de-risking their technology by obtaining experimental data and developing a viable therapeutic intervention, which is crucial before entering clinical trials.